Ann: Change of Share Registry, page-18

I think it relates to the fees paid to the Anderson Cancer Center for the license to use their DKK1.
"Exact amount paid is un-disclosed"

Arovella Therapeutics (formerly SUDA Pharmaceuticals) has announced it has in-licensed the rights to a novel monoclonal antibody that targets the Dickkopf-1 (DKK1) peptide from MD Anderson Cancer Center (for undisclosed upfront and development milestones as well as single digit royalties). DKK1 has been shown to promote tumour metastasis across a variety of tumour types. The company plans to combine the DKK1 targeting technology with its recently acquired invariant natural killer T (iNKT) cell therapy platform and test DKK1-CAR-iNKT cells (under programme name ALA-104) in cancer models in 2022.